Over the past 12 months, 9 insiders at Adaptive Biotechnologies Corp filed 109 open-market SEC Form 4 transactions on ADPT: 0 purchases worth $0 and 109 sales worth $88.2M. Insiders have been net sellers over this period. The most recent filing was on Jul 15, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jul 15, 26 | Francis LoChief People Officer | SELL | 105.8K | $22.59 | $2.4M |
| Jul 2, 26 | Harlan S RobinsChief Scientific Officer | SELL | 239.4K | $22.45 | $5.2M |
| Jul 2, 26 | Francis LoChief People Officer | SELL | 44.8K | $22.59 | $1.0M |
| Jul 1, 26 | Susan BobulskyChief Commercial Officer, MRD | SELL | 487 | $22.00 | $11K |
| Jul 1, 26 | Francis LoChief People Officer | SELL | 42.3K | $22.50 | $951K |
| Jun 29, 26 | Sharon BenzenoChief Commercial Ofc Imm Med | SELL | 154.8K | $21.14 | $3.3M |
| Jun 26, 26 | Sharon BenzenoChief Commercial Ofc Imm Med | SELL | 11.0K | $21.00 | $232K |
| Jun 25, 26 | Susan BobulskyChief Commercial Officer, MRD | SELL | 5.0K | $20.50 | $103K |
| Jun 25, 26 | Michelle Renee Griffin | SELL | 52.1K | $20.18 | $1.1M |
| Jun 16, 26 | Harlan S RobinsChief Scientific Officer | SELL | 6.2K | $18.01 | $111K |
| Jun 15, 26 | Harlan S RobinsChief Scientific Officer | SELL | 100.0K | $17.37 | $1.7M |
| Jun 11, 26 | Susan BobulskyChief Commercial Officer, MRD | SELL | 5.0K | $19.00 | $95K |
| Jun 4, 26 | Susan BobulskyChief Commercial Officer, MRD | SELL | 11.0K | $18.00 | $198K |
| Jun 4, 26 | Francis LoChief People Officer | SELL | 39.7K | $17.49 | $695K |
| May 18, 26 | Kyle PiskelChief Financial Officer | SELL | 3.1K | $13.04 | $41K |
| Apr 27, 26 | Julie RubinsteinPresident and COO | SELL | 19.0K | $14.23 | $271K |
| Apr 24, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.02 | $267K |
| Apr 23, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.74 | $262K |
| Apr 22, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.13 | $269K |
| Apr 21, 26 | Julie RubinsteinPresident and COO | SELL | 30.9K | $14.66 | $454K |
| Apr 20, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.55 | $277K |
| Apr 17, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.57 | $278K |
| Apr 16, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.18 | $270K |
| Apr 15, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.61 | $278K |
| Apr 14, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.56 | $278K |
| Apr 13, 26 | Julie RubinsteinPresident and COO | SELL | 15.7K | $14.08 | $204K |
| Apr 10, 26 | Julie RubinsteinPresident and COO | SELL | 18.7K | $13.48 | $238K |
| Apr 9, 26 | Julie RubinsteinPresident and COO | SELL | 17.0K | $14.44 | $234K |
| Apr 8, 26 | Francis LoChief People Officer | SELL | 22.6K | $15.07 | $340K |
| Apr 8, 26 | Harlan S RobinsChief Scientific Officer | SELL | 10.0K | $14.85 | $149K |
| Apr 8, 26 | Chad M RobinsCEO and Chairman | SELL | 37.3K | $15.19 | $566K |
| Apr 8, 26 | Julie RubinsteinPresident and COO | SELL | 30.8K | $15.48 | $457K |
| Apr 7, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.56 | $258K |
| Apr 6, 26 | Chad M RobinsCEO and Chairman | SELL | 83.3K | $14.41 | $1.2M |
| Apr 6, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.33 | $273K |
| Mar 31, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.45 | $256K |
| Mar 30, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $12.63 | $241K |
| Mar 27, 26 | Julie RubinsteinPresident and COO | SELL | 16.3K | $13.48 | $220K |
| Mar 26, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.12 | $269K |
| Mar 25, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $14.27 | $272K |
| Mar 24, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.70 | $261K |
| Mar 23, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.83 | $264K |
| Mar 20, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.37 | $255K |
| Mar 19, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.18 | $251K |
| Mar 18, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.18 | $251K |
| Mar 17, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.40 | $255K |
| Mar 16, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $13.41 | $256K |
| Mar 13, 26 | Julie RubinsteinPresident and COO | SELL | 19.1K | $12.96 | $247K |
| Mar 12, 26 | Julie RubinsteinPresident and COO | SELL | 13.7K | $13.43 | $173K |
| Mar 11, 26 | Sharon BenzenoChief Commercial Ofc Imm Med | SELL | 63.1K | $13.17 | $831K |
Over the past 12 months, insiders at Adaptive Biotechnologies Corp filed 0 open-market purchases worth $0 and 109 sales worth $88.2M on ADPT, which makes them net sellers over the period. The most recent Form 4 was filed on Jul 15, 26.
9 different insiders at Adaptive Biotechnologies Corp filed open-market SEC Form 4 transactions on ADPT over the last 12 months.
InsiderTape plots every ADPT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Adaptive Biotechnologies Corp insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →